On February 11, 2013, Albany Molecular Research Inc. (AMRI) announced that the company signed an exclusive license agreement with Chai Therapeutics, LLC for the development of ALB 109564(a), AMRI’s novel tubulin inhibitor compound in late Phase I testing for the treatment of cancer. This agreement follows the exercise of an option to license the intellectual property, which was granted in March 2012 by AMRI to Bessor Pharma, LLC, a translational drug development company. Chai Therapeutics is an affiliate of Bessor Pharma, LLC. In AMRI’s work to date, ALB 109564(a) has shown significant promise as a next generation tubulin inhibitor for the treatment of cancer.
On August 18, 2008, AMRI announced the initiation of its Phase I study of ALB 109564(a). The study involved intravenous administration of ALB 109564(a) to cancer patients with advanced solid tumors. The study has been designed to evaluate the compound’s safety, tolerability, and pharmacokinetic profile and document effects on tumor growth. Promising results from the Phase I clinical dose-escalation study were published in the November 2010 edition of the European Journal of Cancer Supplements. These results indicate that ALB 109564(a) is well tolerated at the doses tested and shows preliminary evidence of clinical activity in disease types not typically treated with approved vinca alkaloids.
|Image depicts vinorelbine cocrystallized with tubulin|